Business Context and Reporting Period
This Form 6-K filing by Oncolytics Biotech Inc. covers the period of November 6, 2002. The company is a Calgary-based biotechnology firm focused on developing REOLYSIN, a human reovirus therapeutic designed to selectively kill cancer cells. Current clinical activities include a T2 prostate cancer trial and a Phase I/II trial for recurrent malignant glioma.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding corporate governance rather than a financial statement.
Material Changes
The primary material change reported is the appointment of Dr. William A. Cochrane to the Board of Directors. Dr. Cochrane brings extensive experience in the pharmaceutical and biotechnology sectors, having previously served as CEO and Chairman of Connaught Laboratories Ltd. and holding various academic and government health positions.
Guidance, Outlook, and Risks
Management commentary indicates that the company expects to benefit significantly from Dr. Cochrane's contributions to the Board. The strategic outlook remains focused on advancing REOLYSIN as a potential cancer therapeutic. The filing does not explicitly detail new risks, contingencies, or unusual items beyond the standard development risks inherent to clinical trials.
Key Facts for Investor Verification
- Dr. William A. Cochrane has been appointed to the Board of Directors effective November 6, 2002.
- The company is currently conducting clinical trials for prostate cancer and malignant glioma.
- No financial performance data is included in this specific filing.
- The company is listed on the TSX (ONC) and NASDAQ (ONCY).